Trial Profile
A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Middle East respiratory syndrome coronavirus vaccine - Vaccitech (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man
- 04 Nov 2021 According to Vaccitech media release, this trial is part of a collaboration between the University of Oxford's Jenner Institute and the King Abdullah International Medical Research Center (KAIMRC).
- 04 Nov 2021 According to Vaccitech media release, results from this trial were published in The Lancet Microbe.
- 04 Nov 2021 Results published in the Vaccitech Media Release.